VigiPallia : Résultats

IMMUNOTHERAPIE

0 sélectionnée(s) / 19 réponse(s)

Early palliative care of non-small cell lung cancer in the context of immunotherapy

PIENIAZEK, Malgorzata ; PAWLAK, Piotr ; RADECKA, Barbara
Oncology letters, 12/2020, vol.20, n°6, p. 1-11

Identification of factors associated with aggressive end-of-life antitumour treatment - retrospective study of 1282 patients with cancer

DEBOURDEAU, Philippe ; BELKACEMI, Mohamed ; ECONOMOS, Guillaume ; ASSÉNAT, Eric ; HILGERS, Werner ; COUSSIROU, Julie ; UZAN, Sfaya Kouidri ; VASQUEZ, Léa ; DEBOURDEAU, Antoine ; DAURES, Jean Pierre ; SALAS, Sebastien
BMJ supportive and palliative care, 05/11/2020, Pagination inconnue

Document en ligne

Chimeric antigen receptor T cell immunotherapy - what you need to know #393

SEDHOM, Ramy ; GUPTA, Arjun ; EL-JAWAHRI, Areej R.
JOURNAL OF PALLIATIVE MEDICINE, 06/2020, vol.23, n°6, p. 863-864

Immunoradiotherapy as an effective therapeutic strategy in lung cancer - from palliative care to curative intent

CHICAS-SETT, Rodolfo ; ZAFRA-MARTIN, Juan ; MORALES-ORUE, Ignacio ; CASTILLA-MARTINEZ, Juan ; BERENGUER-FRANCES, Miguel A. ; GONZALEZ-RODRIGUEZ, Elisa ; RODRIGUEZ-ABREU, Delvys ; COUNAGO, Felipe
Cancers, 05/08/2020, vol.12, n°8, p. 1-20

Document en ligne

Palliative care in the context of immune and targeted therapies - a qualitative study of bereaved carers' experiences in metastatic melanoma

FOX, Jennifer A. ; ROSENBERG, John ; EKBERG, Stuart ; LANGBECKER, Danette
PALLIATIVE MEDICINE, 27/04/2020, Pagination inconnue

Document en ligne

A phase II study of pembrolizumab in combination with palliative radiotherapy for hormone receptor-positive metastatic breast cancer

BARROSO-SOUSA, Romualdo ; KROP, Ian E. ; TRIPPA, Lorenzo ; TAN-WASIELEWSKI, Zhenying ; LI, Tianyu ; OSMANI, Wafa ; ANDREWS, Chelsea ; DILLON, Deborah ; RICHARDSON, Edward T. ; PASTORELLO, Ricardo G. ; WINER, Eric P. ; MITTENDORF, Elizabeth A. ; BELLON, Jennifer R. ; SCHOENFELD, Jonathan D. ; TOLANEY, Sara M.
Clinical breast cancer, 30/01/2020, Pagination inconnue

Document en ligne

Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors

PETRILLO, Laura A. ; EL-JAWAHRI, Areej ; NIPP, Ryan D. ; LICHTENSTEIN, Morgan R. L. ; DURBIN, Sienna M. ; REYNOLDS, Kerry L. ; GREER, Joseph A. ; TEMEL, Jennifer S. ; GAINOR, Justin F.
Cancer, 06/03/2020, Pagination inconnue

Document en ligne

Anticancer therapy within the last 30 days of life - results of an audit and re-audit cycle from an Australian regional cancer centre

NGUYEN, Mike ; NG YING KIN, Sean ; SHUM, Evonne ; WANN, Alysson ; TAMJID, Babak ; SAHU, Arvind ; TORRES, Javier
BMC palliative care, 27/01/2020, vol.19, n°1, p. 1-10

Document en ligne

Immune checkpoint inhibitor use near the end of life - a single-center retrospective study

GLISCH, Chad ; SAEIDZADEH, Seyedehtanaz ; SNYDERS, Travis ; GILBERTSON-WHITE, Stephanie ; HAGIWARA, Yuya ; LYCKHOLM, Laurel
JOURNAL OF PALLIATIVE MEDICINE, 07/2020, vol.23, n°7, p. 977-979

Document en ligne

Has there been a shift in use of subacute rehabilitation instead of hospice referral since immunotherapy has become available?

YEH, Jonathan C. ; KNIGHT, Louise S. ; KANE, Joyce ; DOBERMAN, Danielle J. ; GUPTA, Arjun ; SMITH, Thomas J.
Journal of oncology practice, 29/08/2019, Pagination inconnue

Document en ligne

Immunotherapy-related adverse effects when treating cancer #375

MATTS, Christina ; BECK, Anna
JOURNAL OF PALLIATIVE MEDICINE, 06/2019, vol.22, n°6, p. 724-725

Document en ligne

Immune checkpoint inhibitor use near the end of life is associated with poor performance status, lower hospice enrollment, and dying in the hospital

GLISCH, Chad ; HAGIWARA, Yuya ; GILBERTSON-WHITE, Stephanie ; GAO, Yubo ; LYCKHOLM, Laurel
The American journal of hospice and palliative care, 03/2020, vol.37, n°3, p. 179-184

Document en ligne

Renal cell carcinoma pseudoprogression with clinical deterioration - to hospice and back

ELIAS, Roy ; KAPUR, Payal ; PEDROSA, Ivan ; BRUGAROLAS, James
Clinical genitourinary cancer, 12/2018, vol.16, n°6, p. 485-488

Document en ligne

Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications

RICCIUTI, Biagio ; DAHLBERG, Suzanne E. ; ADENI, Anika ; SHOLL, Lynette M. ; NISHINO, Mizuki ; AWAD, Mark M.
Journal of clinical oncology, 17/06/2019, Pagination inconnue

Document en ligne

Thème : Médecine.

ANTI INFLAMMATOIRE STEROIDIEN ; DEMARCHE PALLIATIVE ; MALADIE RESPIRATOIRE ; IMMUNOTHERAPIE ; CANCER RESPIRATOIRE

Purpose: Baseline use of corticosteroids is associated with poor outcomes in patients with non-small-cell lung cancer (NSCLC) treated with programmed cell death-1 axis inhibition. To approach the question of causation versus correlation for this association, we examined outcomes in patients treated with immunotherapy depending on whether corticosteroids were administered for cancer-related palliative reasons or cancer-unrelated indications.
Patients and methods: Clinical outcomes in patients with NSCLC treated with immunotherapy who received >= 10 mg prednisone were compared with outcomes in patients who received 0 to < 10 mg of prednisone.
RESULTS: Of 650 patients, the 93 patients (14.3%) who received >= 10 mg of prednisone at the time of immunotherapy initiation had shorter median progression-free survival (mPFS) and median overall survival (mOS) times than patients who received 0 to < 10 mg of prednisone (mPFS, 2.0 v 3.4 months, respectively; P = .01; mOS, 4.9 v 11.2 months, respectively; P < .001). When analyzed by reason for corticosteroid administration, mPFS and mOS were significantly shorter only among patients who received >= 10 mg prednisone for palliative indications compared with patients who received >= 10 mg prednisone for cancer-unrelated reasons and with patients receiving 0 to < 10 mg of prednisone (mPFS, 1.4 v 4.6 v 3.4 months, respectively; log-rank P < .001 across the three groups; mOS, 2.2 v 10.7 v 11.2 months, respectively; log-rank P < .001 across the three groups). There was no significant difference in mPFS or mOS in patients receiving >= 10 mg of prednisone for cancer-unrelated indications compared with patients receiving 0 to < 10 mg of prednisone.
CONCLUSION: Although patients with NSCLC treated with >= 10 mg of prednisone at the time of immunotherapy initiation have worse outcomes than patients who received 0 to < 10 mg of prednisone, this difference seems to be driven by a poor-prognosis subgroup of patients who receive corticosteroids for palliative indications.

Origine : PubMed

Top ten tips for palliative care clinicians caring for cancer patients receiving immunotherapies

WIESENTHAL, Alison C. ; PATEL, Sandip P. ; LEBLANC, Thomas W. ; ROELAND, Eric J. ; KAMAL, Arif H.
JOURNAL OF PALLIATIVE MEDICINE, 05/2018, vol.21, n°5, p. 694-699

Document en ligne

Clinical and palliative care outcomes for patients of poor performance status treated with antiprogrammed death-1 monoclonal antibodies for advanced melanoma

WONG, Annie ; WILLIAMS, Molly ; MILNE, Donna ; MORRIS, Kortnye ; LAU, Peter ; SPRUYT, Odette ; FULLERTON, Sonia ; MCARTHUR, Grant
Asia-Pacific journal of clinical oncology, 06/2017, Pagination inconnue

Document en ligne

Traitement palliatif de l'ascite maligne

ABDESSALEM, Mohamed Karim
MEDECINE PALLIATIVE, Elsevier Masson, 02/2014, vol.13, n°1, p. 34-38

Les traitements du mélanome de la peau

Institut National du Cancer ; Ligue nationale contre le cancer
Institut national du cancer , 10/2010 , 79 p.

Document en ligne

Actions

##titre_notice##